Skip to content

The effect of herbal product from Berberis integerrima on Non-Alcoholic Fatty Liver Disease

The effect of herbal product from Berberis integerrima on ultrasound image echogenicity of patients with Non-Alcoholic Fatty Liver Disease

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20210524051376N1
Enrollment
60
Registered
2021-06-30
Start date
2021-05-31
Completion date
Unknown
Last updated
2021-07-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Fatty liver. Fatty (change of) liver, not elsewhere classified

Interventions

Intervention 1: Intervention group: herbal syrup from Berberis integerrima (75mg /mL) 2 cups (10ml) per day for three months after breakfast and dinner and return to the same centers for ultrasound an

Sponsors

Babol University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
20 Years to 60 Years

Inclusion criteria

Inclusion criteria: Increased liver echogenicity (grade 2 non-alcoholic fatty liver) based on ultrasonographic findings

Exclusion criteria

Exclusion criteria: The underlying illness (Diabetes mellitus, cardiovascular diseases, liver disease (cirrhosis, alcoholic liver disease, viral hepatitis, autoimmune hepatitis, primary biliary cirrhosis, biliary obstruction, hepatic damage induced by hereditary hemochromatosis drugs, sclerosis cholangitis and a deficiency of an antitrypsin), other serious diseases such as cancer; kidney failure and celiac disease Pregnancy Lactation Drug history with increase hepatic steatosis risk (Tamoxifen, valproate sodium, ... Antihyperlipidemic drugs Malnutrition special diets such as vegetarianism and raw eating Alcohol consumption Smoking and addiction Acute psychiatric disorder

Design outcomes

Primary

MeasureTime frame
The ultrasound image echogenicity of patients with Non-Alcoholic Fatty Liver Disease. Timepoint: 3 months after the start of the intervention. Method of measurement: Ultrasonography grading and lab test (TG, LDL,HDL, AST ,ALT).

Secondary

MeasureTime frame
Body wheight. Timepoint: 3 months after the start of the intervention. Method of measurement: Measure weight (kg).

Countries

Iran (Islamic Republic of)

Contacts

Public ContactNarjes Gorji

Babol University of Medical Sciences

n.gorji@mubabol.ac.ir+98 11 3219 9592

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026